INS and hepatocellular carcinoma: To identify novel drug targets that have the potential to enhance insulin sensitivity and decrease HGP, we generated a human hepatoma cell line, AH-G6PC, that stably expressed β-lactamase under the control of the G6PC promoter (Fig. 1A) as described in the “Experimental Procedures” section.